Education
About Us
Working with TipRanks
Follow Us
Ascelia Pharma AB (SE:ACE)
:ACE
ACE Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.89 - kr8.08
Previous CloseN/A
Volume171.87K
Average Volume (3M)758.72K
Market Cap
kr432.78M
Enterprise Valuekr230.73M
Total Cash (Recent Filing)kr219.15M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 16, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding116,025,530
10 Day Avg. Volume807,629
30 Day Avg. Volume758,715
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Ascelia Pharma AB News
PremiumCompany Announcements
Ascelia Pharma’s AGM: Key Resolutions and Strategic Authorizations
PremiumPre-Earnings
Is 7ZA a Buy, Before Earnings?
---
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr1.89 and its highest was kr8.08 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr432.78M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is May 16, 2025 which is in 8 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on Feb 07, 2025. The company reported -kr0.295 earnings per share for the quarter, missing the consensus estimate of -kr0.138 by -kr0.157.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate is -0.2.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 116,025,530 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.295 in its last earnings report, missing expectations of -kr0.138. Following the earnings report the stock price went up 5.594%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
---
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
---
Technical Analysis
Immunicum AB
―
Isofol Medical AB
―
NextCell Pharma AB
―
Xbrane Biopharma AB
―
Xintela AB
―
---